Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 4 1Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Desmoid Tumors 1

Interventions

Imatinib Mesylate 3nilotinib 2Sunitinib 2Ibandronic Acid 2Doxorubicin 2Cyclophosphamide 2regorafenib 1pegylated granulocyte colony-stimulating factor 1nirogacestat 1avapritinib 1anlotinib 1Zoledronic Acid 1Tranexamic Acid 1Thiotepa 1Ritonavir 1Radiotherapy 1Pregabalin 1Oxaliplatin 1Nevirapine 1Midazolam 1Lopinavir 1Lithium Carbonate 1Lead 1Kyphoplasty 1Indocyanine Green 1Ifosfamide 1Hyperbaric Oxygenation 1Filgrastim 1Esomeprazole 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × nirogacestat × Sarcoma × Clear all
NCT07176689 2026-05-08

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 4 Recruiting
50 enrolled
Sarcoma

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡